World Health Organization (WHO). Seasonal influenza vaccines: an overview for decision-makers. 2020.
CBG. Samenvatting van de Productkenmerken—NL SPC Influvac Tetra. 2022.
CBG. Samenvatting van de productkenmerken—Vaxigrip Tetra. 2022.
World Health Organization (WHO). Influenza (Seasonal) 2023. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).
Heins M, Hooiveld M, Korevaar J. Vaccine Coverage Dutch National Influenza Prevention Program 2019: brief monitor. 2020.
Gezondheidsraad. Griepvaccinatie: herziening van de indicatiestelling 2021. Den Haag: Gezondheidsraad; 2021.
Dhakal S, Klein SL. Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J Virol. 2019. https://doi.org/10.1128/JVI.00797-19.
Article PubMed PubMed Central Google Scholar
Denly L. The effect of sex on responses to influenza vaccines. Hum Vaccin Immunother. 2021;17(5):1396–402.
EMA. Guideline on good pharmacovigilance practices (GVP)—annex I—definitions (Rev 4). 2017. Report No.: EMA/873138/2011 Rev 2, 6/144.
van Balveren-Slingerland L, Kant A, Härmark L. Web-based intensive monitoring of adverse events following influenza vaccination in general practice. Vaccine. 2015;33(19):2283–8.
Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Hum Vacc Immunother. 2019;15(11):2624–36.
Lv H, Pan X, Liang H, Wang Y, Hu Y. Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine. Hum Vacc Immunother. 2021;17(11):4617–22.
Stefanizzi P, De Nitto S, Spinelli G, Lattanzio S, Stella P, Ancona D, et al. Post-marketing active surveillance of adverse reactions following influenza cell-based quadrivalent vaccine: an Italian prospective observational study. Vaccines. 2021;9(5):456.
Article PubMed PubMed Central Google Scholar
Kini A, Morgan R, Kuo H, Shea P, Shapiro J, Leng SX, et al. Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race. Vaccine. 2022;40(11):1643–54.
Hammarström A, Annandale E. A conceptual muddle: an empirical analysis of the use of ‘sex’ and ‘gender’ in ‘gender-specific medicine’ journals. PLoS ONE. 2012;7(4): e34193.
Article PubMed PubMed Central Google Scholar
Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9–15.
Article CAS PubMed PubMed Central Google Scholar
Tadount F, Doyon-Plourde P, Rafferty E, MacDonald S, Sadarangani M, Quach C. Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females? —A systematic review. Vaccine. 2020;38(3):444–59.
Article CAS PubMed Google Scholar
Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination strategies. J Infect Dis. 2014;209(Suppl 3):S114–9.
Article CAS PubMed PubMed Central Google Scholar
Du J, Cai Y, Chen Y, Tao C. Trivalent influenza vaccine adverse symptoms analysis based on MedDRA terminology using VAERS data in 2011. J Biomed Semantics. 2016;7:1–7.
Shapiro JR, Seddu K, Park H-S, Lee JS, Creisher PS, Yin A, et al. The intersection of biological sex and gender in adverse events following seasonal influenza vaccination in older adults. 2023.
Duijster JW, Lieber T, Pacelli S, Van Balveren L, Ruijs LS, Raethke M, et al. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: a Dutch cohort study and review of the literature. Front Immunol. 2023;14.
Härmark L, van Grootheest K. Web-based intensive monitoring: from passive to active drug surveillance. Expert Opin Drug Saf. 2012;11(1):45–51.
Härmark L, van Hunsel F, Hak E, van Grootheest K. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring. Vaccine. 2011;29(10):1941–7.
Brighton Collaboration. Brighton Collaboration case definitions 2023. https://brightoncollaboration.us/category/pubs-tools/case-definitions/.
MedDRA. MedDRA 2022. https://www.meddra.org/].
McEvoy SP. A retrospective survey of the safety of trivalent influenza vaccine among adults working in healthcare settings in south metropolitan Perth, Western Australia, in 2010. Vaccine. 2012;30(17):2801–4.
Spila Alegiani S, Alfonsi V, Appelgren EC, Ferrara L, Gallo T, Alicino C, et al. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season. BMC Public Health. 2018;18(1):1401.
Article PubMed PubMed Central Google Scholar
Kumabe A, Kenzaka T, Yahata S, Goda K, Okayama M. Evaluation of adverse reactions to influenza vaccination: a prospective cohort study. Vaccines. 2022;10(10):1664.
Article PubMed PubMed Central Google Scholar
Bohn-Goldbaum E, Cross T, Leeb A, Peters I, Booy R, Edwards KM. Adverse events following influenza immunization: understanding the role of age and sex interactions. Expert Rev Vaccines. 2022;21(3):415–22.
Article CAS PubMed Google Scholar
Haq K, McElhaney JE. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol. 2014;29:38–42.
Article CAS PubMed Google Scholar
Scheifele DW, Bjornson G, Johnston J. Evaluation of adverse events after influenza vaccination in hospital personnel. CMAJ. 1990;142(2):127–30.
CAS PubMed PubMed Central Google Scholar
Van der Maas N, Godefrooij S, Vermeer-de Bondt P, de Melker H, Kemmeren J. Tolerability of 2 doses of pandemic influenza vaccine (Focetria®) and of a prior dose of seasonal 2009–2010 influenza vaccination in the Netherlands. Hum Vacc Immunother. 2016;12(4):1027–32.
Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine. 2015;33(9):1151–9.
Article CAS PubMed Google Scholar
Cross JW, Joy M, McGee C, Akinyemi O, Gatenby P, de Lusignan S. Adverse events of interest vary by influenza vaccine type and brand: sentinel network study of eight seasons (2010–2018). Vaccine. 2020;38(22):3869–80.
Harris T, Nair J, Fediurek J, Deeks SL. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–15. Vaccine. 2017;35(19):2600–4.
Vasileiou E, Sheikh A, Butler C, El Ferkh K, von Wissmann B, McMenamin J, et al. Effectiveness of influenza vaccines in asthma: a systematic review and meta-analysis. Clin Infect Dis. 2017;65(8):1388–95.
Article PubMed PubMed Central Google Scholar
Bechini A, Ninci A, Del Riccio M, Biondi I, Bianchi J, Bonanni P, et al. Impact of influenza vaccination on all-cause mortality and hospitalization for pneumonia in adults and the elderly with diabetes: a meta-analysis of observational studies. Vaccines. 2020;8(2):263.
Article PubMed PubMed Central Google Scholar
Gupta C, Sachdeva A, Khamar J, Bu C, Bartoszko J, Loeb M. Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: a systematic review and meta-analysis. Vaccine. 2022.
World Health Organization (WHO). Causality Assessment of an Adverse Event Following Immunization (AEFI). User Manual for the Revised WHO Classification. 2018.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenza-en pneumokkenvaccinatie—rapportage 2020-2021. 2021.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenzavaccinaties—rapportage 2019-2020. 2020.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen griepvaccins—Rapportage seizoen 2013-2014 2014 [Available from: https://www.lareb.nl/media/qqlfbfka/jaarrapportage-griepvaccins-2013-2014.pdf.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenzavaccinatie—rapportage 2014-2015 2015.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenzavaccinatie—rapportage 2015-2016. 2016.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenzavaccinatie—rapportage influenzaseizoen 2016-2017. 2017.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenzavaccinatie—rapportage influenzaseizoen 2017-2018. 2018.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenzavaccinatie—rapportage influenzaseizoen 2018-2019. 2019.
Netherlands Pharmacovigilance Centre Lareb. Meldingen van bijwerkingen na influenza- en pneumokokkenvaccinatie—rapportage vaccinatiecampagne seizoen 2021-2022 2022.
Comments (0)